M

MicroGenDX

Performs qPCR+NGS infectious disease testing

Overview

Temporary placeholder

Work here?Claim your company

About MicroGenDX

Simplify's Rating
Why MicroGenDX is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Orlando, FL

Founded

2008

Get referred to MicroGenDX

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • MicroGenDX opened a larger Lubbock lab in January 2025, expanding capacity.
  • MicroGenDX launched Rapid H5 in February 2025 for H5 influenza detection.
  • MicroGenDX expanded internationally with Labor Dr. Fenner and MicroGenDX EU in April 2025.

What critics are saying

  • MicroGenDX's own materials still frame NGS as adjunctive, not standard-of-care.
  • Overdiagnosis and overtreatment remain explicit AUA concerns around molecular infection diagnostics.
  • If reimbursement weakens, MicroGenDX's 100-plus hospital agreements lose conversion power quickly.

What makes MicroGenDX unique

  • MicroGenDX delivered 24-hour NGS after sample receipt using Illumina MiSeq i100 Plus.
  • MicroGenDX combines qPCR and NGS in one report across 20 clinical panels.
  • MicroGenDX won AUA 2025 recognition for NGS in recurrent UTI care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance

Company News

Newswire
Feb 28th, 2025
MicroGenDX Launches "Rapid H5," a PCR Test for H5 Influenza Detection

LUBBOCK, Texas, February 28, 2025 (Newswire.com) - MicroGenDX, a leader in clinical molecular diagnostics, is launching Rapid H5, a qPCR test designed to detect H5 avian influenza A variants, such as H5N1, the current bird flu strain.

PharmiWeb
May 2nd, 2024
MicroGenDX Launches Its Patient-Focused Website to Streamline Access to Microbial Testing

MicroGenDX launches its Patient-Focused Website to streamline Access to Microbial Testing.

PharmiWeb
Jan 31st, 2024
Study Unlocks New Hope In The Battle Against Male Infertility

A new study from UCLA and MicroGenDX shows that bacteria may be one of the factors holding back male fertilityORLANDO, FL / ACCESSWIRE / January 31, 2024 / A groundbreaking study conducted by researchers at the University of California Los Angeles (UCLA) and MicroGenDX unveils a potential link between bacterial profiles and male infertility. The collaborative effort, highlighted in the study Semen microbiota are dramatically altered in men with abnormal sperm parameters by Osadchiy et al., sheds crucial light on microbial variations associated with abnormal sperm parameters. This significant discovery not only deepens our comprehension of male infertility, but also provides a new exploratory avenue for treatments facilitated by MicroGenDX's advanced testing.Differential Relative Abundance. Only statistically significant differences are shown. Figure 1A-C, represent the comparisons of groups 1, 2 and 3, respectively.While pollution and other environmental factors have long been recognized as contributors to declining sperm counts, the revelation of bacterial involvement poses a new challenge in the battle against male infertility. Male fertility concerns have historically weighed heavily on individuals whose aspirations of fatherhood are jeopardized by factors often beyond their control

Femtech Insider
Dec 13th, 2022
Evvy Partners with MicroGenDX to Relaunch its Metagenomics-based Vaginal Health Test – Femtech Insider

Evvy, a female-founded startup on a mission to close the gender health gap by discovering and leveraging female-specific biomarkers, is now partnering with MicroGenDX, a CLIA/CAP certified laboratory that has been pioneering the use of NGS testing for physicians for over a decade.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for MicroGenDX right now.

Find jobs on Simplify and start your career today

We update MicroGenDX's jobs every few hours, so check again soon!Browse all jobs